SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (1897)4/2/2003 7:39:02 PM
From: scaram(o)uche  Read Replies (1) of 2243
 
>> Will a medimmune pull through and have 3 amev derived compounds in the clinic this year? <<

Putting my "507" bias aside, I'd still bet "no". Anti-angiogenesis isn't as hot as when the project was conceived. For cancer, that's a given. It's not that it won't contribute to static disease some day, but that it's a long, hard road. For RA, the incredible success using anti-TNF and advances in small molecule programs makes it high risk, IMO.

And I also feel that FluMist changed their entire perspective...... opportunism at it's best, and it will probably breed more.

But I still don't see any dents in the numax rationale.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News